AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.
Clinical Trials
2
1 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
1
50.0%
Recruiting
1
50.0%
No approval data available
- Sellas Life Sciences' Phase 3 REGAL study of galinpepimut-S in AML is nearing final analysis with 78 of 80 required events reported, while updated executive severance agreements fuel acquisition speculation. - Moderna highlighted progress across oncology, autoimmune, and rare disease programs at its Science Day, including mRNA-2808, an investigational T-cell engager for multiple myeloma. - AbCellera Biologics secured a research collaboration with Jazz Pharmaceuticals for multispecific T-cell engager antibodies targeting gastrointestinal cancers, with $56 million in upfront funding for the first two programs.
- ResearchAndMarkets.com has released a comprehensive report analyzing licensing deals in biotechnology from 2020 to 2025, providing insights into deal trends and structures. - The report covers hundreds of companies including major players like AbbVie, ACADIA Pharmaceuticals, and emerging biotech firms across various therapeutic areas and technology types. - Key features include financial terms analysis covering upfront payments, milestones, and royalties, plus access to actual contract documents for due diligence purposes. - The analysis enables benchmarking of transaction values and identification of the most active dealmakers in the biotechnology licensing landscape.
- AbCellera Biologics has received Health Canada authorization to begin Phase 1 trials for ABCL635, a first-in-class NK3R antagonist targeting menopause-related hot flashes, and ABCL575, an OX40L-targeting antibody for atopic dermatitis, both scheduled to start in Q3 2025. - The company's strategic shift from partnership-driven revenue to internal drug development resulted in Q1 2025 revenue declining to $4.2 million from $10 million year-over-year, while maintaining $811 million in total liquidity to fund operations through 2026. - ABCL635 targets a $2 billion menopause market with its monthly subcutaneous dosing profile, potentially offering advantages over existing daily oral therapies like Fezolinetant and Elinzanetant. - The company is completing an in-house GMP manufacturing facility by year-end 2025 to reduce third-party reliance and lower long-term production costs.
